Zhou Qun, Huang Shao-Xin, Zhang Feng, Li Shu-Jun, Liu Cong, Xi Yong-Yong, Wang Liang, Wang Xin, He Qi-Qiang, Sun Cheng-Cao, Li De-Jia
Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, Hubei, 430071, China.
Department of Social Medicine and Public Health, School of Basic Medical Science, Jiujiang University, Jiujiang, Jiangxi, China.
Cell Prolif. 2017 Dec;50(6). doi: 10.1111/cpr.12394. Epub 2017 Oct 8.
Lung cancer is still one of the most serious causes of cancer-related deaths all over the world. MicroRNAs (miRNAs) are defined as small non-coding RNAs which could play a pivotal role in post-transcriptional regulation of gene expression. Increasing evidence demonstrated dysregulation of miRNA expression associates with the development and progression of NSCLC.
To emphasize a variety of tissue-specific miRNAs, circulating miRNAs and miRNA-derived exosomes could be used as potential diagnostic and therapeutic biomarkers in NSCLC patients.
MATERIALS & METHODS: In the current review, we paid attention to the significant discoveries of preclinical and clinical studies, which performed on tissue-specific miRNA, circulating miRNA and exosomal miRNA. The related studies were obtained through a systematic search of Pubmed, Web of Science, Embase.
A variety of tissue-specific miRNAs and circulating miRNAs with high sensitivity and specificity which could be used as potential diagnostic and therapeutic biomarkers in NSCLC patients. In addition, we emphasize that the miRNA-derived exosomes become novel diagnostic biomarkers potentially in these patients with NSCLC.
MiRNAs have emerged as non-coding RNAs, which have potential to be candidates for the diagnosis and therapy of NSCLC.
肺癌仍是全球癌症相关死亡的最主要原因之一。微小RNA（miRNA）被定义为小型非编码RNA，其在基因表达的转录后调控中发挥关键作用。越来越多的证据表明，miRNA表达失调与非小细胞肺癌（NSCLC）的发生和发展相关。
强调多种组织特异性miRNA、循环miRNA和miRNA衍生的外泌体可作为NSCLC患者潜在的诊断和治疗生物标志物。
在本综述中，我们关注了针对组织特异性miRNA、循环miRNA和外泌体miRNA开展的临床前和临床研究的重要发现。相关研究通过对PubMed、科学网、Embase进行系统检索获得。
多种具有高敏感性和特异性的组织特异性miRNA和循环miRNA可作为NSCLC患者潜在的诊断和治疗生物标志物。此外，我们强调miRNA衍生的外泌体可能成为这些NSCLC患者新的诊断生物标志物。
miRNA已作为非编码RNA出现，有潜力成为NSCLC诊断和治疗的候选物。
